UPDATE 1-GlobeImmune, Gilead Hep B drug fails in mid-stage study
May 27, 2015 at 07:31 AM EDT
May 27 (Reuters) - GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial.
